Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Geraldine O.’Sullivan Coyne, Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M. Covey, Jan H. Beumer, Mihaela C. Cristea, Edward M. Newman, Stephen Koehler, Jorge J. Nieva, Agustin A. Garcia, David R. Gandara, Brandon Miller, Sonny Khin, Sarah B. Miller, Seth M. Steinberg, Larry Rubinstein, Ralph E. Parchment, Robert J. Kinders, Richard L. PiekarzShivaani Kummar, Alice P. Chen, James H. Doroshow

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint Dive into the research topics of 'Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds